-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)

Sponsor: educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb and Lilly
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Friday, December 8, 2023: 3:00 PM-6:00 PM
Grand Ballroom, 4 (Omni San Diego)
Neil Love, MD, Research To Practice
No relevant conflicts of interest to declare.
Farrukh T. Awan, MD, The University of Texas , Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute , Stephen J. Schuster, MD, University of Pennsylvania , William G. Wierda, MD, PhD, University of Texas MD Anderson Cancer Center and Jennifer A. Woyach, MD, The Ohio State University Comprehensive Cancer Center
Awan: Pharmacyclics LLC, an AbbVie Company.: Other: Contracted Research; Janssen, Gilead, Kite pharmaceuticals, Karyopharm, MEI Pharma, Verastem, Incyte, Johnson and Johnson, Merck, Epizyme, Loxo Oncology, Adaptive Biotechnologies, Genmab: Other: Consulting Agreements; AstraZeneca Pharmaceuticals LP: Other: Advisory Committee; AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Cardinal Health, Caribou Biosciences Inc, Celgene Corporation, Cellectar Biosciences Inc, DAVA Oncology, Epizyme Inc, Genentech, a member of the Roche: Other: Consulting Agreements. Davids: ONO Pharmaceuticals: Consultancy; Novartis: Research Funding; Aptitude Health: Consultancy; BeiGene: Consultancy; Eli Lilly: Consultancy; Ascentage Pharma: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Secura Bio: Consultancy; Mingsight Pharmaceuticals: Consultancy; TG Therapeutics: Consultancy, Research Funding; Research to Practice: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Curio Science: Consultancy; BMS: Consultancy; Adaptive Biosciences: Consultancy; MEI Pharma: Research Funding; Surface Oncology: Research Funding; Merck: Consultancy; AbbVie: Consultancy, Research Funding. Schuster: Nordic Nanovector: Other: Scientific Advisory Committee; Merck: Research Funding; Janssen Research & Development: Research Funding; Gilead: Research Funding; Celgene: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Genentech: Consultancy; Acerta: Consultancy. Wierda: National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL). Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; KITE Pharma: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; Janssens Biotech: Research Funding; AbbVie: Consultancy, Research Funding; Numab THerapeutics: Research Funding; Accutar Biotechnology: Research Funding; Nurix THerapeutics: Research Funding; Janssens Biotech Inc: Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding; Genentech: Research Funding; GSK/Novartis: Research Funding; Gilead Sciences: Research Funding; Cyclacel: Consultancy, Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Juno Therapeutics: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; Pharmacyclics LLC: Research Funding; NIH P30 CA016672/MDACC Cancer Center Support Grant: Research Funding; GlaxoSmithKline: Research Funding; Sunesis: Research Funding; Miragen: Research Funding. Woyach: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Newave Pharmaceutical Inc, Pharmacyclics LLC, an AbbVie: Other: Advisory Committee and Consulting Agreements; AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.: Other: Contracted Research.
On Demand program will be available here soon. For questions, please reach out to the managing company contact from Research to Practice, listed below.

This CME-accredited program, offered for in-person and virtual attendees, will focus on the management of chronic lymphocytic leukemia (CLL). Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty member” investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this same survey and share the scientific rationale.

At the live event, for each module, Dr Love will present results from the survey, followed by video excerpts from the non-faculty member interviews. The faculty panel will be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have the opportunity to provide feedback on the same survey and present their own questions for discussion.